CO6721019A2 - Quinazolincarboxamida azetidinas - Google Patents

Quinazolincarboxamida azetidinas

Info

Publication number
CO6721019A2
CO6721019A2 CO13144136A CO13144136A CO6721019A2 CO 6721019 A2 CO6721019 A2 CO 6721019A2 CO 13144136 A CO13144136 A CO 13144136A CO 13144136 A CO13144136 A CO 13144136A CO 6721019 A2 CO6721019 A2 CO 6721019A2
Authority
CO
Colombia
Prior art keywords
quinazolincarboxamide
azetidines
cancer
formula
treatment
Prior art date
Application number
CO13144136A
Other languages
English (en)
Inventor
Bayard R Huck
Reinaldo Jones
Yufang Xiao
Constantin Neagu
Donald Bankston
Andreas Goutopoulos
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of CO6721019A2 publication Critical patent/CO6721019A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención proporciona nuevos compuestos de quinazolincarboxamida azetidina de acuerdo con la fórmula (I) y su uso para el tratamiento de enfermedades hiperproliferativas tales como el cáncer.
CO13144136A 2010-11-24 2013-06-17 Quinazolincarboxamida azetidinas CO6721019A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41713110P 2010-11-24 2010-11-24

Publications (1)

Publication Number Publication Date
CO6721019A2 true CO6721019A2 (es) 2013-07-31

Family

ID=45001695

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13144136A CO6721019A2 (es) 2010-11-24 2013-06-17 Quinazolincarboxamida azetidinas

Country Status (31)

Country Link
US (1) US8946247B2 (es)
EP (1) EP2643313B9 (es)
JP (1) JP5897590B2 (es)
KR (1) KR101894116B1 (es)
CN (1) CN103228649B (es)
AR (1) AR093725A1 (es)
AU (1) AU2011334173B2 (es)
BR (1) BR112013012488B1 (es)
CA (1) CA2818706C (es)
CL (1) CL2013001459A1 (es)
CO (1) CO6721019A2 (es)
DK (1) DK2643313T3 (es)
EA (1) EA023821B1 (es)
ES (1) ES2594404T3 (es)
HK (1) HK1188444A1 (es)
HR (1) HRP20161183T1 (es)
HU (1) HUE028967T2 (es)
IL (1) IL226233A (es)
LT (1) LT2643313T (es)
MX (1) MX355325B (es)
MY (1) MY186456A (es)
NZ (1) NZ612224A (es)
PE (1) PE20140966A1 (es)
PL (1) PL2643313T3 (es)
PT (1) PT2643313T (es)
RS (1) RS55204B1 (es)
SG (1) SG190318A1 (es)
SI (1) SI2643313T1 (es)
UA (1) UA112167C2 (es)
WO (1) WO2012069146A1 (es)
ZA (1) ZA201304637B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX346095B (es) 2011-09-12 2017-03-07 Merck Patent Gmbh Nuevas imidazol-aminas como moduladores de la actividad de cinasas.
SI2755958T1 (sl) 2011-09-12 2017-12-29 Merck Patent Gmbh Aminopirimidinski derivati za uporabo kot modulatorji kinazne aktivnosti
CN105102435A (zh) 2012-11-16 2015-11-25 默克专利有限公司 用作激酶活性调节剂的新颖的咪唑-哌啶基衍生物
AU2013344552B2 (en) 2012-11-16 2018-03-15 Xiaoling Chen Novel heterocyclic derivatives as modulators of kinase activity
BR112015011974A8 (pt) 2012-11-29 2019-10-08 Merck Patent Gmbh derivados de azaquinazolina carboxamida, seus usos e processo para sua produção, medicamento e composição farmacêutica
KR20150124957A (ko) 2013-03-11 2015-11-06 메르크 파텐트 게엠베하 키나아제 활성의 조절인자로서 (6-[4-1h-이미다졸-2-일)피페리딘-1-일]피리미딘-4-아민 유도체
NZ725361A (en) * 2014-04-03 2022-09-30 Merck Patent Gmbh Combinations of cancer therapeutics
NZ731770A (en) * 2014-12-11 2023-05-26 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative
US20190054110A1 (en) * 2016-02-16 2019-02-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of ccr9 for treating tumor resistance to immune responses
WO2017140803A1 (en) * 2016-02-16 2017-08-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modulators of tumor immune resistance for the treatment of cancer
EP3762379A1 (en) 2018-03-07 2021-01-13 Bayer Aktiengesellschaft Identification and use of erk5 inhibitors
WO2021094209A1 (en) 2019-11-12 2021-05-20 Bayer Aktiengesellschaft Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
AU2021376892A1 (en) 2020-11-16 2023-06-29 Merck Patent Gmbh Kinase inhibitor combinations for cancer treatment
US11866421B2 (en) * 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment
WO2024033513A1 (en) 2022-08-11 2024-02-15 Diaccurate Compounds for treating cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JPWO2004014873A1 (ja) * 2002-08-09 2005-12-02 杏林製薬株式会社 ４−置換キナゾリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
EP1615906A1 (en) 2003-04-03 2006-01-18 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
WO2005033086A1 (en) 2003-09-30 2005-04-14 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1678168B1 (en) 2003-10-24 2012-07-11 Exelixis, Inc. P70s6 kinase modulators and method of use
AU2004295061B2 (en) 2003-11-21 2008-11-20 Novartis Ag 1H-imidazoquinoline derivatives as protein kinase inhibitors
CN1889958A (zh) 2003-12-09 2007-01-03 美国政府健康及人类服务部 抑制免疫应答或治疗增生性疾病的方法
CA2563699C (en) 2004-04-23 2014-03-25 Exelixis, Inc. Kinase modulators and method of use
JP5274842B2 (ja) 2004-12-28 2013-08-28 エグゼリクシス， インコーポレイテッド 免疫疾患、炎症疾患および増殖疾患の処置のためのセリン−スレオニンキナーゼモジュレーター（ｐ７０Ｓ６Ｋ、Ａｋｔ−１およびＡｋｔ−２）としての［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジンまたは［１Ｈ−ピペラゾ［３，４−ｄ］ピリミジン−４−イル］−ピペラジン化合物
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
JP2008546751A (ja) 2005-06-22 2008-12-25 アステックス・セラピューティクス・リミテッド 医薬組成物
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
DE102007032739A1 (de) 2007-07-13 2009-01-15 Merck Patent Gmbh Chinazolinamidderivate
EA020731B1 (ru) * 2009-02-11 2015-01-30 Мерк Патент Гмбх Аминоазагетероциклические карбоксамиды
CN103140484B (zh) * 2010-07-29 2015-04-22 默克专利有限公司 环状胺氮杂杂环甲酰胺
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди

Also Published As

Publication number Publication date
BR112013012488A2 (pt) 2016-07-19
HK1188444A1 (zh) 2014-05-02
KR101894116B1 (ko) 2018-08-31
PL2643313T3 (pl) 2017-03-31
ZA201304637B (en) 2014-03-26
CN103228649A (zh) 2013-07-31
MX2013005751A (es) 2013-08-01
AR093725A1 (es) 2015-06-24
LT2643313T (lt) 2016-10-25
MX355325B (es) 2018-04-16
MY186456A (en) 2021-07-22
JP5897590B2 (ja) 2016-03-30
NZ612224A (en) 2015-01-30
BR112013012488B1 (pt) 2021-08-31
CN103228649B (zh) 2015-11-25
AU2011334173B2 (en) 2015-07-16
IL226233A0 (en) 2013-07-31
JP2013544257A (ja) 2013-12-12
ES2594404T3 (es) 2016-12-20
WO2012069146A1 (en) 2012-05-31
HRP20161183T1 (hr) 2016-11-04
HUE028967T2 (en) 2017-01-30
CL2013001459A1 (es) 2013-12-27
DK2643313T3 (en) 2016-10-24
PT2643313T (pt) 2016-10-11
EP2643313A1 (en) 2013-10-02
US20130252942A1 (en) 2013-09-26
CA2818706A1 (en) 2012-05-31
EA201300610A1 (ru) 2013-12-30
AU2011334173A1 (en) 2013-05-02
EA023821B1 (ru) 2016-07-29
EP2643313B1 (en) 2016-06-29
KR20130130753A (ko) 2013-12-02
RS55204B1 (sr) 2017-01-31
IL226233A (en) 2017-07-31
CA2818706C (en) 2019-07-23
UA112167C2 (uk) 2016-08-10
US8946247B2 (en) 2015-02-03
SG190318A1 (en) 2013-06-28
PE20140966A1 (es) 2014-08-06
SI2643313T1 (sl) 2016-11-30
EP2643313B9 (en) 2017-02-22

Similar Documents

Publication Publication Date Title
CO6721019A2 (es) Quinazolincarboxamida azetidinas
CR20130045A (es) Compuestos terapéuticos
DOP2014000062A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
BR112013003671A2 (pt) composições e métodos para melhorar os benefícios terapêuticos de compostos químicos administyrados sub-otimamente incluindo hexitóis substituídos tais como dianidrogalactitol e diacetildianidrogalactiol
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
UY33735A (es) Compuestos antivirales
EA201300730A1 (ru) Производные индазолилтриазола
CL2010001641A1 (es) Compuestos derivados de heterociclos biciclicos sustituidos; composicion farmaceutica; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas e inflamatorias tales como cancer y artritis reumatoide entre otras.
UA108101C2 (xx) Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів
EA201590005A1 (ru) Замещенные трициклические соединения как ингибиторы fgfr
UA110354C2 (uk) Противірусні сполуки
EA201491766A1 (ru) Соединения для лечения спинальной мышечной атрофии
CR20120113A (es) (heteroarilmetil)tiohidantoinas sustituidas como drogas anticancer
MX2012001419A (es) Compuestos biciclicos novedosos de urea.
EA201491412A1 (ru) Соединения для лечения спинальной мышечной атрофии
MX343561B (es) Compuestos de imidazolpiridazina.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
CR20140071A (es) Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa
MX353299B (es) Metodos y composiciones relacionadas con p62 para el tratamiento y profilaxis del cancer.
ECSP11010867A (es) Compuestos novedosos de fenilamino-isonicotinamida
EA201491817A1 (ru) Терапевтическое применение продуктов из косточек винограда шардоне
MX2012001413A (es) Compuestos azaheterociclicos novedosos.
IN2015DN01119A (es)
GEP201706710B (en) Imidazopyridazine derivatives as gabaa receptor modulators
EA201400339A1 (ru) Новые имидазоламины в качестве модуляторов киназной активности